AG
RNAM

Algert Global’s Avidity Biosciences RNAM Stock Holding History

Algert Global’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,391
Closed -$1.06M – 1309
2024
Q4 		$1.06M Sell
36,391
-1,862
-5% -$77.8K 0.02% 773
2024
Q3 		$1.76M Sell
38,253
-4,310
-10% -$187K 0.05% 601
2024
Q2 		$1.74M Buy
42,563
+10,443
+33% +$300K 0.06% 511
2024
Q1 		$820K Buy
+32,120
New +$503K 0.03% 666
2023
Q2 		– Sell
-63,230
Closed -$971K – 1226
2023
Q1 		$971K Buy
+63,230
New +$1.39M 0.05% 647

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's RNAM Position: Q1 2025 in Review

Algert Global sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 36,391 shares — an estimated $1.06M sold.

Algert Global first reported a position in RNAM in Q1 2023 and held it in 5 quarters. The position peaked at $1.76M in Q3 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • Algert Global reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • Algert Global sold 36,391 Avidity Biosciences shares in Q1 2025, an estimated $1.06M.
  • Algert Global first reported a position in Avidity Biosciences in Q1 2023 and held it in 5 quarters.
  • Algert Global's Avidity Biosciences position peaked at $1.76M in Q3 2024.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Algert Global's 13F filing for Q1 2025, filed 13 May 2025.